Veterinarians in Chicago are studying two anti‑aging drugs for dogs to determine whether they can slow aging and improve long‑term health. Common signs of aging in dogs include physical changes such as graying and thinning fur, particularly around the muzzle, vision and hearing loss, and reduced mobility due to arthritis and joint issues.

The work underway aims to move beyond treatments for individual diseases and test whether medications can alter the ageing process itself, potentially changing how veterinarians manage the health of older dogs. Researchers say the studies could also offer new insights into biological ageing that are relevant across species. The new anti-aging drugs for dogs, particularly LOY-002 and rapamycin, represent a significant shift in approach compared to existing treatments for age-related issues, as they target the underlying biological mechanisms rather than simply addressing individual age-associated diseases after they develop. For more information, see What dogs are teaching us about aging, with Daniel Promislow.

Local veterinarians and collaborating researchers are recruiting and monitoring dogs as they receive the investigational medications, following them for measures that include physical function, behavior and general health. Clinicians track changes over time to judge whether the treatments produce measurable benefits for animals as they age. The average lifespan for dogs varies significantly depending on breed size and genetics, with small breeds often living 10-15 years and some reaching 18. What is the average lifespan of dogs by breed, and how might anti-aging drugs affect this?

Veterinary trials of this kind typically combine clinical examinations, owner-reported observations and standardized assessments to evaluate whether an intervention affects everyday health and activity. Those assessments help clinicians determine whether a drug improves mobility, cognitive engagement or resilience to age-related decline, rather than merely treating one specific condition. With small dog breeds often living 10-15 years, and some even reaching 18, the implications of these studies could be far-reaching.

Companion dogs are a focus for ageing research because their lifespans and living environments allow scientists to study long‑term effects on health within a time frame that is shorter than human studies. For broader background on how dogs are being used to study ageing, readers can see the University of Chicago feature on the topic.

Study teams are also looking at practical questions for owners and clinics: how to monitor older animals receiving new medications, what side‑effect profiles may emerge in routine practice, and how to weigh potential benefits against risks over time. Those operational issues shape whether an effective drug can be adopted widely in primary‑care veterinary settings. How do these new anti-aging drugs compare to existing treatments for age-related issues?

Researchers emphasize careful measurement. Trials aim to detect consistent improvements across multiple indicators of health, rather than isolated changes in a single test. That approach helps distinguish a true slowing of biological ageing from short‑term or placebo effects.

The trials form part of a growing interest in interventions that target the ageing process itself. Scientific coverage of companion‑animal ageing, and how studies on dogs could translate to other species, provides context for why clinicians and owners are watching these studies closely; a review of longevity differences by dog breed offers additional statistical context.

Veterinarians involved in the work are advising owners of older dogs to maintain routine care and to discuss any experimental treatment with their clinic before enrolling. Clinical teams use established safeguards during trials to monitor animals and respond to adverse reactions, and they collect data that will inform future recommendations on dosing and monitoring.

The studies now in progress will report findings as investigators complete follow‑up assessments and analyze the accumulated data. Those results will determine whether the drugs slow markers of ageing and, importantly, whether any such effects translate into longer periods of healthy life for treated animals.

Source

Original reporting: view the original article.